Lilly earnings guidance indicates 2025 sales of Zepbound and Mounjaro exceeding $36 billion, surpassing Wall Street expectations.
Author: PharmaSignal News Desk
Amgen inflammatory drug faces regulatory scrutiny as the company refuses FDA’s withdrawal request, impacting its market strategy.
FDA PreCheck program opens to pharmaceutical facilities aligning with national priorities, impacting AstraZeneca and Acadia drugs.
PharmaSignal Take This week’s events signal a continued trend of strategic acquisitions and partnerships, alongside regulatory advancements and setbacks. Notably, AstraZeneca’s massive investment in China’s drug development and Halozyme’s acquisition of a biotech startup stress-test the assumption of integration risk and platform scalability. These decisions will have significant implications for post-close activities and portfolio strategy. The PharmaSignal Weekly Brief – Global Pharma Roundup this week highlights themes of M&A activity, regulatory acceleration, and pipeline risk. M&A and Strategic Deals AstraZeneca’s $15B investment in China’s drug development signals a strategic move to capitalize on the growing Asian market. The deal’s success…
AstraZeneca China investment of $15B aims to enhance drug research and development capabilities.
Tenpoint FDA approval marks a significant step for its presbyopia eye drop, supported by $235 million in funding.
Halozyme acquires a biotech startup for up to $400 million, enhancing its drug delivery capabilities.
Regenxbio gene therapy trials for Hunter and Hurler syndromes are suspended by the FDA due to safety concerns involving a brain tumor.
A senior BD execution signal from this month’s most instructive pharma deal.
Intellia CRISPR trial resumes after FDA hold lifted. New safeguards are in place following a participant’s death.